Physician profile
Robert W Demetrius
NPI 1386603009
$266.95
in general payments reported to CMS, 2019-2025
6 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $77.78 · 2024: $57.28 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $84.86 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $63.06 | 2025 | |
| Smith+Nephew, INC. | $36.85 | 2024 | Renasys Go V2 Home |
| Kerecis Limited | $31.85 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Genzyme Corporation | $28.10 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.23 | 2025 | Siliq, Cabtreo, Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Demetrius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.